All In Biotech

Drug Trial Radar · NCT06075537

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

99

Planned (sponsor's estimate)

Start

Sep 20, 2023

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Denali Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multiregional open-label extension (OLE) to assess the safety, tolerability, and efficacy of long-term treatment with tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant intravenous (IV) enzyme replacement therapy (ERT) for Hunter syndrome (MPS II). Participants who complete at least through the Week 49 visit in Study DNLI-E-0002 and do not discontinue study intervention early and participants who complete Study DNLI-E-0007 will be enrolled in this OLE. All participants will receive DNL310 for up to 5 years from the time of entry in this OLE. Participants, site staff, and the Sponsor will remain blinded to the original treatment assignment for participants entering this OLE from Study DNLI-E-0007.

Conditions

  • Mucopolysaccharidosis II

Interventions

  • tividenofusp alfaDrug

    Intravenous repeating dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and intensity of treatment-emergent adverse events (TEAEs)Time frame: 5 years
  2. Clinically significant changes in urine total glycosaminoglycan (GAG) concentrations throughout the treatment periodTime frame: 5 years
  3. Incidence and intensity of infusion-related reactions (IRRs)Time frame: 5 years

Locations

32 sites in 14 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Ann and Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • UNC Children's Research Institute

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • The University of Texas Medical School at Houston

    Houston, Texas

  • Huntsman Cancer Hospital

    Salt Lake City, Utah

  • Sanatorio Mater Dei

    Buenos Aires, Argentina

  • UZ Brussel

    Jette, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Antwerpen, Belgium

  • Hospital Clinicas Porto Alegre

    Porto Alegre, Brazil

  • University of Alberta - Faculty of Medicine & Dentistry

    Edmonton, Alberta, Canada

  • Hospital for Sick Children

    Toronto, Ontario, Canada

  • McGill University Health Center

    Montreal, Quebec, Canada

  • Vseobecna Fakultni Nemocnice V Praze

    Prague, Czechia

  • Hopital Jeanne De Flandre - Metabolic Diseases Unit

    Lille, France

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • SpinCS GmbH

    Höchheim, Germany

  • ASST di Cremona

    Cremona, Italy

  • Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia

    Udine, Italy

  • Erasmus Medical Center - Sophia Children's Hospital

    Rotterdam, Netherlands

  • Hospit U. Vall d'Hebron - PPDS

    Barcelona, Spain

  • Hospital Infantil Universitario Niño Jesús

    Madrid, Spain

  • Drottning Silvias Barn Och Ungdomssjukhus

    Gothenburg, Sweden

  • University Medical Faculty Balcali Hospital

    Adana, Turkey (Türkiye)

  • Gazi Universitesi Tip Fakultes

    Ankara, Turkey (Türkiye)

  • Birmingham Women's and Children's NHS Foundation Trust

    Birmingham, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • Salford Royal Hospital

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.